WASHINGTON — The Food and Drug Administration announced on Wednesday that it would require its toughest warning labels to caution patients against taking opioid painkillers together with benzodiazepines, like Xanax and Valium. The combination makes an overdose more likely and the warning is aimed at making sure people understand that.
Benzodiazepines are prescribed for anxiety, insomnia and seizures, and opioids for pain. The drugs work by depressing the central nervous system. Increasingly, doctors have been prescribing them together. The number of patients who were prescribed both drugs rose by 41 percent — about 2.5 million people — from 2002 to 2014, the agency said.
But the combination can result in extreme sleepiness, coma and death. The agency said a review of emergency room data in the United States showed that the overdose death rate involving both drugs tripled from 2004 to 2011. About a third of opioid overdose deaths in 2011 involved a benzodiazepine.
The two classes of drugs already carry cautions against using both together. But the changes announced on Wednesday made those warnings far tougher. The move was part of a broader federal effort to reduce deaths from drug overdoses, which are now more numerous than deaths from car crashes in the United States.
Eighty-one million patients received opioids in 2014, up by 8 percent since 2002, the agency said, and 30 million received a benzodiazepine, up by 31 percent.
Experts said the new labels were good for raising awareness about the danger of taking both drugs, but were skeptical that they would change practices.
“I don’t think these warnings have much of an impact,” said Dr. Andrew Kolodny, the executive director of Physicians for Responsible Opioid Prescribing. He said a more muscular move would be to limit how drug companies can market opioids.
But health officials argued that the tougher labels would have an effect because so many of the prescriptions — about half in 2014 — were dispensed on the same day and written by the same doctor.
“This is going to reset the conversation about the use of these two products together,” said Dr. Doug Throckmorton, deputy director of the Center for Drug Evaluation and Research at the F.D.A.
By Sabrina Tavernese - The NY Times/Aug. 31, 2016
Illustration: Can Stock
Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.